Divarasib is a medication being studied for its effectiveness in treating advanced or metastatic non-small cell lung cancer that has a specific genetic mutation known as KRAS G12C. This medication is being compared to other treatments to see if it can help patients live longer without their cancer getting worse.

Sotorasib is a medication used to treat non-small cell lung cancer with the KRAS G12C mutation. It works by targeting and inhibiting the activity of the mutated KRAS protein, which is involved in the growth and spread of cancer cells.

Adagrasib is another treatment option for non-small cell lung cancer with the KRAS G12C mutation. Like sotorasib, it targets the KRAS protein to help stop the cancer from growing and spreading. This study is comparing its effectiveness to divarasib.

KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer characterized by a specific genetic mutation in the KRAS gene, known as G12C. It primarily affects the cells lining the lungs and is classified as non-small cell, which is the most common type of lung cancer. The disease is considered advanced or metastatic when it has spread beyond the lungs to other parts of the body. As the cancer progresses, it can lead to symptoms such as persistent cough, chest pain, and difficulty breathing. The presence of the KRAS G12C mutation can influence the behavior of the cancer and its response to certain treatments. Understanding the mutation is crucial for developing targeted therapies aimed at slowing the progression of the disease.